Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $17.77 USD
Change Today -0.38 / -2.09%
Volume 148.2K
SUPN On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 10:20 AM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

supernus pharmaceuticals inc (SUPN) Snapshot

Open
$17.64
Previous Close
$18.15
Day High
$18.03
Day Low
$17.57
52 Week High
08/5/15 - $23.30
52 Week Low
10/27/14 - $7.31
Market Cap
860.9M
Average Volume 10 Days
777.0K
EPS TTM
$0.83
Shares Outstanding
48.4M
EX-Date
--
P/E TM
21.4x
Dividend
--
Dividend Yield
--
Current Stock Chart for SUPERNUS PHARMACEUTICALS INC (SUPN)

supernus pharmaceuticals inc (SUPN) Related Bloomberg News

View More Bloomberg News

supernus pharmaceuticals inc (SUPN) Related Businessweek News

No Related Businessweek News Found

supernus pharmaceuticals inc (SUPN) Details

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its marketed products include Oxtellar XR, an extended-release oxcarbazepine and Trokendi XR, an extended-release topiramate, which are neurology products used for the treatment of epilepsy. The company products also comprise SPN-810, a molindone hydrochloride that has completed Phase II clinical trials for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which has completed Phase IIa clinical trials for the treatment of ADHD. In addition, it is developing SPN-809, a viloxazine hydrochloride as a once-daily product candidate for the treatment of depression. The company markets its products through wholesalers and pharmaceutical distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.

309 Employees
Last Reported Date: 03/12/15
Founded in 2005

supernus pharmaceuticals inc (SUPN) Top Compensated Officers

Founder, Chief Executive Officer, President, ...
Total Annual Compensation: $485.7K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $317.9K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $342.4K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $314.8K
Compensation as of Fiscal Year 2014.

supernus pharmaceuticals inc (SUPN) Key Developments

Supernus Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Revised Earnings Guidance for the Full Year of 2015

Supernus Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $35,052,000 against $29,675,000 a year ago. Operating income was $3,076,000 against $3,756,000 a year ago. Net income was $2,005,000 or $0.03 per basic and diluted share against $3,202,000 or $0.08 per basic and diluted share a year ago. For the six months, the company reported total revenues of $63,185,000 against $38,756,000 a year ago. Operating income was $6,507,000 against loss of $9,667,000 a year ago. Net income was $2,923,000 or $0.06 per basic and diluted share against net loss of $12,342,000 or $0.30 per basic and diluted share a year ago. The company is updating its full year 2015 financial guidance for both expected net product sales and operating income. The company expects that net product sales will range from $135 million to $140 million, with operating income ranging from $8 million to $10 million. This compares to prior guidance of net product sales of $130 million to $140 million and operating income of $6 million to $10 million. The company continues to expect that research and development expenses will increase by greater than 50% in 2015 as compared to 2014 as the company progresses the development of SPN-810 and SPN-812.

Supernus Pharmaceuticals, Inc. to Report Q2, 2015 Results on Aug 04, 2015

Supernus Pharmaceuticals, Inc. announced that they will report Q2, 2015 results on Aug 04, 2015

Supernus Pharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 05, 2015

Supernus Pharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 05, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SUPN:US $17.68 USD -0.47

SUPN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $61.01 USD +1.45
Cosmo Pharmaceuticals SA SFr.158.00 CHF -1.00
Depomed Inc $26.79 USD -0.14
Durect Corp $2.06 USD 0.00
Veloxis Pharmaceuticals A/S kr1.02 DKK -0.03
View Industry Companies
 

Industry Analysis

SUPN

Industry Average

Valuation SUPN Industry Range
Price/Earnings 27.2x
Price/Sales 5.8x
Price/Book 8.4x
Price/Cash Flow 24.5x
TEV/Sales 5.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUPERNUS PHARMACEUTICALS INC, please visit www.supernus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.